Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

Abstract

The use of anticholinergic drugs by people with overactive bladder syndrome results in statistically significant improvement in symptoms. However, the clinical significance of these differences is uncertain, and the longer-term effects are not known. Dry mouth is a common side effect of therapy.

Antimuscarinics: properties and use in overactive bladder

“…4 On the other hand, the efficacy and clinical significance of anticholinergics has been reviewed, 5 challenging the apparent discrepancy between the statistical significance of anticholinergics in trials and the 'modest improvement in quality of life'. 6 Furthermore, the overall discontinuation rate of anticholinergics in randomised, double-blind clinical trials was reported to be 4 to 31 per cent, with discontinuation due to adverse events or side-effects observed to range between 0 and 21 per cent. Newer preparations, eg solifenacin, do not necessarily carry a lower discontinuation rate compared with the old generation, eg tolterodine.…”

Overactive Bladder Syndrome: Considerations in Pharmacotherapy and New Perspectives

“…Oxybutynin is usually prescribed at the dose of 5 mg twice a day with the possibility to increase it up to 10 mg 3 times a day [11] . The use of slow-release systems of oxybutynin could improve patient compliance when compared to the immediate-release formulation [12] , although some data are controversial [13] .…”

“…Tolterodine is a relatively new antimuscarinic drug characterized by a greater selectivity for the lower urinary tract compared to oxybutynin; this brings about a significant decrease in side-effects allowing a better treatment compliance in the long term [12][13][14][15][16][17][18][19] . It is available in an immediate-release and in an extended-release formulation.…”

Urinary incontinence - treatment

“…Diese sollte man unter Berücksichtigung der Einstellung der Patientin und Indikation anwenden (10) . …”